NewcelX is a clinical-stage drug development company focusing on neurobehavioral and neurocognitive disorders and their pharmacognosia.
NewcelX (formerly NLS Pharma) has raised $1.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
NewcelX (formerly NLS Pharma)'s investors include Biotechnology Value Fund, Yorkville Advisors.
NewcelX (formerly NLS Pharma) is headquartered in Stans, Switzerland.
NewcelX is a clinical-stage drug development company focusing on neurobehavioral and neurocognitive disorders and their pharmacognosia.
NewcelX (formerly NLS Pharma) is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NewcelX (formerly NLS Pharma) — Funding & Investors." VCBacked, April 1, 2026, https://www.vcbacked.co/company/newcelx-formerly-nls-pharma. Accessed August 18, 2026.
VCBacked. (2026). NewcelX (formerly NLS Pharma) — Funding & Investors. Retrieved August 18, 2026, from https://www.vcbacked.co/company/newcelx-formerly-nls-pharma
{{cite web |title=NewcelX (formerly NLS Pharma) — Funding & Investors |url=https://www.vcbacked.co/company/newcelx-formerly-nls-pharma |website=VCBacked |access-date=August 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated